ANI PHARMACEUTICALS INC

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) operates as a diversified biopharmaceutical company with a mission to serve patients and improve lives through the development, manufacturing, and commercialization of therapeutics. The company maintains its website at www.anipharmaceuticals.com.

ANI organizes its business into three primary segments: Rare Disease, Brands, and Generics and Other. The Rare Disease segment includes foundational assets such as Purified Cortrophin Gel, a purified corticotropin product approved for treating chronic autoimmune disorders including multiple sclerosis and rheumatoid arthritis, as well as the Retina Franchise acquired through the September 2024 acquisition of Alimera Sciences. This franchise comprises ILUVIEN and YUTIQ, ophthalmology products with ILUVIEN approved for treating diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. The Brands segment markets various branded pharmaceutical products including Atacand, Arimidex, Casodex, Inderal formulations, Lithobid, Vancocin, and Veregen, among others. The Generics and Other segment encompasses a portfolio of more than 120 generic products developed through internal research and development, acquisitions, and strategic partnerships, with the company expecting approximately ten to fifteen new product launches annually.

ANI operates three pharmaceutical manufacturing facilities, including two in Baudette, Minnesota and one in East Windsor, New Jersey, capable of producing oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products requiring fully-contained manufacturing environments. The company manufactures certain key products including Cortrophin Gel and ILUVIEN through third-party contract manufacturers.

The company expanded its geographic footprint through the Alimera acquisition, which included direct marketing operations in Germany, the United Kingdom, Portugal, and Ireland, along with partnerships across Europe, Asia, and the Middle East. ANI's diversified portfolio reflects a strategy of combining organic growth with strategic acquisitions of businesses, abbreviated new drug applications, new drug applications, and product rights. The company maintains robust research and development capabilities, particularly following its 2021 acquisition of Novitium Pharma LLC, which significantly enhanced generic pharmaceutical development and manufacturing expertise.